ASH 2014 – CLL

Frontline Chemoimmunotherapy with Fludarabine/Cyclophosphamide/Rituximab versus Bendamustine/Rituximab in Advanced CLL: Final Analysis of the CLL10 Study

ASH 2014 – CLL

Interim Analysis of Phase 2 ICLL01: Ofatumumab and High-Dose Methylprednisolone in Patients at Highest Risk for Relapsed/Refractory CLL

ASH 2014 – CLL

Functional Evidence that Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death

ASH 2014 – CLL

The Combination of Alemtuzumab and Ofatumumab in Previously Untreated CLL

ASH 2014 – CLL

Ublituximab plus TGR-1202 in Heavily Pretreated and High-Risk CLL

ASH 2014 – CLL

Ibrutinib in Relapsed/Refractory CLL After Allogeneic Stem-Cell Transplant

ASH 2014 – CLL

Dinaciclib plus Ofatumumab in Patients with Relapsed/Refractory CLL

ASH 2014 – CLL

Ibrutinib versus Ofatumumab in Patients with Relapsed/Refractory CLL in the RESONATE Study

ASH 2014 – CLL

The FCR2 Regimen: A Phase 2 Study of FCR-Lite and Lenalidomide in Frontline CLL

ASH 2014 – CLL

Idelalisib plus Rituximab for Relapsed CLL: Interim Analysis in Subpopulations with del17p and Other Adverse Prognostic Factors

ASH 2014 – CLL

Page 1 of 3

1
2
3